S. Korea’s Celltrion Partners with US firm Abpro for breast cancer treatment

South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10

Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.

Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.

The Massachusetts-based Abpro is developing eight other cancer treatment candidates.

ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.